Participant flow

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) · Source last updated 2026-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).

   id

   FG000

   title

   Pembrolizumab

2. description

   Participants received placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles (up to approximately 1 year).

   id

   FG001

   title

   Placebo

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         18

      2. group Id

         FG001

         num Subjects

         33

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         11

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         463

      2. group Id

         FG001

         num Subjects

         454

      type

      Ongoing on trial follow up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         496

      2. group Id

         FG001

         num Subjects

         498

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         488

      2. group Id

         FG001

         num Subjects

         496

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Continuing Study Treatment

   4. achievements

      1. group Id

         FG000

         num Subjects

         298

      2. group Id

         FG001

         num Subjects

         365

      type

      Completed Study Treatment

   5. achievements

      1. group Id

         FG000

         num Subjects

         190

      2. group Id

         FG001

         num Subjects

         130

      type

      Discontinued Study Treatment

   6. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      comment

      Completed Trial

      type

      COMPLETED

   7. achievements

      1. group Id

         FG000

         num Subjects

         496

      2. group Id

         FG001

         num Subjects

         498

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Of the 994 participants randomized in the study, 984 participants received study medication and were evaluable for safety analyses (Database cutoff date 14 Dec 2020)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice